Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMimetic Ramps Up R&D For Synthetic Bone Products

This article was originally published in The Gray Sheet

Executive Summary

Combination products firm BioMimetic expects rapid enrollment this fall in a U.S. pivotal study of a product to facilitate fusions in the foot and ankle, CEO Samuel Lynch said during an Aug. 14 earnings call

You may also be interested in...



BioMimetic Aims To Complete Bone Graft Study Enrollment By Year-End

BioMimetic Therapeutics is hoping enrollment in an ongoing pivotal trial for its Augment Bone Graft will be complete by year-end despite a recent slowdown in registration

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel